New study maps wildlife microbiota

Credit: Pixabay/CC0 Public Domain

Wild Biotech, a preclinical stage drug discovery & development company emerging out of stealth mode, today announces the publication of its first major paper, which appears in the journal Science. The study mapped the gut microbiota of animals in the wild on an unprecedented scale, adding millions of potentially novel microbiome-based therapeutics for human diseases to the company's already massive database. Wild will use these findings to first tap its database for targets in inflammatory, immune and gastrointestinal diseases.

"For the study, we collected gut microbiota from almost 200 species of in the wild, covering diverse classes, feeding behaviors, geographies, and traits," said Neta Raab, Co-founder & Chief Executive Officer at Wild Biotech. "Using de novo metagenome assembly, we constructed and functionally annotated a of over 5,000 from those animals covering more than 1,200 bacterial species—75% of which were previously unknown."

Animals in the wild exhibit extraordinary feats of survival. Some, from hyenas and jackals to Tasmanian devils, subsist on rotting, pathogen-infected and toxic food while remaining immune to —possible due, in part, to their gut microbiota. While the understanding of the diversity and functions within these ecosystems is poor, the microbial composition, diversity, and functional content of animals' microbiota have known associations with animal taxonomy, diet, activity, social structure and lifespan. "These are clues which we could tap into in order to discover entirely new agents to treat human diseases," Raab said.

The findings reported in Science add 30 million genes—each representing a potentially new therapeutic agent—to Wild's unique database of animal microbiota, which now comprises hundreds of animal species and 100 million genes. "The majority of that genomic material is novel, and our database introduces thousands of previously undescribed species into the bacterial tree of life," Raab said.

Wild applies cutting-edge AI tools to decipher the therapeutic potential of its database and identify proteins, peptides, bacteriophages, and other agents with direct activity on targets in human diseases. The company's database is unique because, unlike microbes found in the ocean or soil, the of animals is the most relevant and directly translatable to human therapeutics.

Wild Biotech's database and AI tools are complemented by high-throughput synthetic biology to validate microbiome-derived agents and accelerate them into preclinical testing, and the high quality of the data extracted from microbial genomes enables the company to directly synthesize and test agents. For example, in the Science study the team synthesized a panel of previously-undescribed enzymes from carrion eater and showed that they operate on a range of microbial toxins, suggesting a mechanism that detoxifies carrion for its safe consumption by the host animal.

The company has also identified in its database over 2,000 CRISPR/Cas genome editing systems, of which approximately one third does not belong to any known CRISPR/Cas family.

"Intractable diseases require new thinking on intervention. Wild has built a revolutionary approach and the tools to explore its novel data sets, unlike any other company," said Dr. John Baldoni, leading pharmaceutical industry expert and advisor to Wild. "You must have the data in order to do the computational work. Because of their highly evolved and relevant library, they are able to look at millions of interactions quickly, within days, and screen and target logical therapeutic areas. Wild's approach enables a translatable workflow from its microbiome data to molecular mechanisms associated with complex diseases."

"We are balancing innovation and clinical evidence to screen many millions of interactions with specific targets associated with human diseases," said Raab. "We are very excited about the extraordinary potential hidden in this database for identifying entirely novel approaches to treat disease."

Explore further

Domestication and industrialisation lead to similar changes in gut microbiota

More information: D. Levin el al., "Diversity and functional landscapes in the microbiota of animals in the wild," Science (2021). … 1126/science.abb5352
Journal information: Science

Provided by Wild Biotech
Citation: New study maps wildlife microbiota (2021, March 25) retrieved 28 June 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors